AAP
COGT icon

Arax Advisory Partners’s Cogent Biosciences COGT Stock Holding History

Arax Advisory Partners’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-18
Closed -$639 – 3901
2025
Q4 		$639 Sell
18
-356
-95% -$10K ﹤0.01% 3565
2025
Q3 		$5.37K Buy
+374
New +$4.43K ﹤0.01% 2847
2024
Q4 		– Sell
-28
Closed -$303 – 2495
2024
Q3 		$303 Hold
28
– – ﹤0.01% 2474
2024
Q2 		$237 Buy
+28
New +$212 ﹤0.01% 2427

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Arax Advisory Partners's COGT Position: Q1 2026 in Review

Arax Advisory Partners sold out of Cogent Biosciences (COGT) in Q1 2026, closing a stake of 18 shares — an estimated $639 sold.

Arax Advisory Partners first reported a position in COGT in Q2 2024 and held it in 4 quarters. The position peaked at $5.37K in Q3 2025. 305 funds tracked by Wall St. Rank hold COGT as of Q1 2026.

  • Arax Advisory Partners reported no remaining Cogent Biosciences position as of Q1 2026 after selling out during the quarter.
  • Arax Advisory Partners sold 18 Cogent Biosciences shares in Q1 2026, an estimated $639.
  • Arax Advisory Partners first reported a position in Cogent Biosciences in Q2 2024 and held it in 4 quarters.
  • Arax Advisory Partners's Cogent Biosciences position peaked at $5.37K in Q3 2025.
  • 305 funds tracked by Wall St. Rank held Cogent Biosciences as of Q1 2026.

Based on Arax Advisory Partners's 13F filing for Q1 2026, filed 13 May 2026.